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Medicalisation is defined by the World Health Organization as a situation in which female genital 
mutilation/cutting (FGM/C) “is practiced by any category of health-care provider, whether in a public 
or private clinic, at home, or elsewhere” (WHO, 2010: 2). Despite the emergence of international 
consensus that female genital mutilation/cutting (FGM/C) is a violation of human rights, a focus on 
medicalisation remains salient because of concerns that FGM/C is increasingly being performed 
by healthcare professionals and may be impeding progress toward abandonment of FGM/C. To 
investigate these claims, this study draws on nationally-representative survey data from 26 
countries, and addresses the following three questions:  
• What are the major patterns and trends in medicalisation?  
• Is there an association between medicalisation and rates of change in prevalence of 
FGM/C?  
• Is there an association between medicalisation and support for the continuation of the 
practice?  
Results show that among women ages 15-49 years, the majority (79%) report having been cut by 
a traditional cutter, while an estimated 21 percent—totalling nearly 16 million girls and women— 
report having been cut by a health care provider. Medicalised cutting is concentrated in three 
countries; 93 percent of women who report having undergone medicalised FGM/C live in Egypt, 
Sudan, and Nigeria. Elsewhere medicalised cutting is rare or restricted to geographic pockets.  
Data on practitioners of FGM/C among daughters show that most cutting is carried out by 
traditional cutters in all countries except Egypt and Sudan, where daughter medicalisation rates 
are 78.4 percent and 77.5 percent, respectively. Mother-daughter comparisons reveal that in select 
countries, rates of medicalisation are increasing—most sharply in Egypt, where the medicalisation 
rate among daughters is nearly twice that of women. Successive survey data show that rising 
medicalisation rates are found in countries where FGM/C rates are steady (Sudan) or dropping 
(Egypt and Kenya), but overall across countries, there is no correlation between medicalisation 
rates among daughters and rates of decline in FGM/C. National-level figures on medicalised 
cutting of daughters are not correlated with higher support for the continuation of FGM/C. Hence, 
it not clear that medicalisation undermines the ability to change attitudes against FGM/C. National-
level figures may mask important locally divergent factors influencing medicalisation and obscure 




At a United Nations summit held in 2015, world leaders adopted a new set of goals and targets 
known as the Sustainable Development Goals (SDGs), outlining a development agenda for the 
next 15 years. SDG target 5.3.2 calls for the elimination of all harmful traditional practices, including 
female genital mutilation/cutting (FGM/C), by the year 2030. FGM/C refers to a variety of practices 
involving the partial or total removal of the external female genitalia for non-therapeutic reasons. 
These range from nicking the tissue surrounding the clitoris to the complete removal of the external 
genitalia. WHO has classified different types of FGM/C as follows: Type I (clitoridectomy) involves 
removal of all or part of the clitoris and/or the prepuce; Type II (excision) involves removal of the 
clitoris and the labia minora with or without removal of the labia majora; Type III (infibulation) 
involves removal of all of the external genitalia, and appositioning the labia to form a seal, leaving 
a pinhole opening for the passage of urine and blood; and Type IV, all unclassified forms, including 
nicking, pricking, and scraping the skin covering or near the clitoris, but no removal of tissue (WHO, 
2008). FGM/C occurs in countries extending from West to East Africa, through the Horn of Africa, 
and in parts of the Middle East and Southeast Asia. Surveys conducted across parts of Africa, the 
Middle East, and Southeast Asia document FGM/C prevalence rates ranging from 1% (Uganda, 
Cameroon) to more than 95% (Guinea and Somalia) (Shell-Duncan, Naik, & Feldman-Jacobs, 
2016; UNICEF, 2016). Although survey data are lacking, FGM/C has been described in countries 
including Colombia, Iran, India, Malaysia, Oman, Pakistan, Russia, and Thailand, as well as in 
migrant communities throughout the world originating from countries where FGM/C is practised 
(BBC, 2016; Merli, 2012; UNICEF, 1998UNICEF, 2016). It has been estimated that worldwide, 
more than 200 million girls and women have undergone some form of FGM/C (UNICEF, 2016), 
and more than 3 million girls are estimated to be at risk of being cut each year. A growing body of 
research has documented that most forms of FGM/C can cause not only immediate health 
complications such as excessive bleeding and infection, but also long-lasting genito-urinary, 
obstetrical, and psychological problems (Berg, Denison, & Fretheim, 2010; Berg, Underland, 
Odgaard-Jensen, Fretheim, & Vist, 2014; WHO, 2006).  
Global efforts to end FGM/C have intensified over the last four decades through combined efforts 
of international and non-governmental organisations, governments, religious and civil society 
groups. A wide range of intervention strategies have been implemented with the goal of 
accelerating abandonment of FGM/C. Initially, the most common approaches used information and 
education campaigns that sought to educate people about the adverse health outcomes 
associated with FGM/C. It was assumed that as people became increasingly aware of negative 
health risks, they would weigh this against the perceived positive aspects, and become motivated 
to abandon the practice (Muteshi & Sass, 2005). Increasingly health education campaigns were 
complemented by more comprehensive strategies such as intergenerational dialogue programmes 
that facilitate conversation and critical assessment of FGM/C among members of practising 
communities (Muteshi & Sass, 2005), holistic community education programmes that culminate in 
public declarations to abandon FGM/C (WHO, 1999), and alternative rites of passage programmes 
that encourage upholding ceremonial aspects of girls’ initiation but eliminating the cutting aspect 
(Chege, Askew, & Liku, 2001; Hernlund, 2000). Most, to some extent, include education on 
adverse medical risks. 
There has been speculation that a focus on health consequences of FGM/C may have 
inadvertently led to medicalisation of the practice (Carr, 1997; WHO, 2010). An early comparative 
overview of data on practitioners of FGM/C from Demographic and Health Survey (DHS) data drew 
attention to the “problem” that in certain settings FGM/C was being increasingly performed by 
health care providers (Carr, 1997). It also characterised declines in FGM/C prevalence as “limited 
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and slow,” with the practice still supported by large segments of the population (Carr, 1997). This 
has led to ongoing speculation that messaging on health risks motivated medicalisation more so 
than abandonment, thereby impeding progress toward abandonment (Carr, 1997; WHO, 2010). 
However, divergent views exist, with debates being centred on the question of whether 
medicalisation can be a viable harm reduction strategy that can serve as a step toward 
abandonment, or whether it legitimises the practice and promotes its perpetuation. During these 
ongoing debates, claims about trends in medicalisation and its effect on the continuation of FGM/C 
are based on limited empirical data. 
Advocates of harm reduction have argued that a shift toward medicalised cutting can represent a 
transitional step toward abandonment (Obiora, 1997). This shift may reflect an openness to 
reassessing the way in which FGM/C is performed, including the possibility of not performing it at 
all (Dawson, Homer, Turkmani, Black, & Varol, 2015; Gele, Bo, & Sundby, 2013; Modrek & 
Sieverding, 2016). A study analysing the 2008 Egypt DHS data found that households were less 
likely to opt for FGM/C when medicalisation was more common among their daughter’s peers; the 
authors suggested that medicalisation may be associated with changing norms surrounding 
FGM/C, opening possibilities for abandonment (Naguib, 2012). It is this logic that belies some, but 
not all, of the policies and measures that have been instituted to minimise harm from FGM/C. In 
countries such as Sudan and Somalia, trainings on FGM/C have been incorporated into the training 
curriculum for health care professionals, with the goal of promoting safer and less severe forms of 
cutting (Boddy, 2007; Gele et al., 2013; Gruenbaum, 1982; Kaphle, 2000; Valderrama, 2002). For 
a period, policies of the ministries of health in Egypt and Indonesia issued directives for FGM/C to 
be performed by health professionals (IRIN_News, September 1, 2011; Reefat, 2009). In parallel, 
beginning in the 1990’s, as host countries received an increased number of immigrants from 
countries where FGM/C is practised, several proposals were drafted to offer hospital-based nicking 
in lieu of more severe forms of cutting (Abdulcadir, Margairaz, Boulvain, & Irion, 2011; Coleman, 
1998; Obiora, 1997). Each of these proposals were met with sharp criticism and have not been 
implemented.  
Opposition to medicalisation is also now endorsed by professional medical organisations around 
the world, including the International Federation of Gynecology and Obstetrics, which passed a 
resolution in 1994 opposing the performance of FGM/C under any circumstances, in health 
establishments or by health professionals (WHO, 2008). On December 20, 2012, the United 
Nations General Assembly passed a Resolution on Intensifying Global Efforts for the Elimination 
of Female Genital Mutilation [A/RC.3/67/L.21/Rev.1]. Its adoption reflects agreement that FGM/C 
constitutes a violation of human rights, and that all countries should take action to end the practice 
“committed within or outside a medical institution, and to take all necessary measures including 
enacting and enforcing legislation to prohibit FGM/C and protect women and girls from this form of 
violence, and to end impunity” [A/RC.3/67/L.21/Rev.1]. Currently 27 countries in Africa and the 
Middle East where FGM/C is practised have banned it by law or constitutional decree (Shell-
Duncan et al., 2016), and in at least six of these countries (Burkina Faso, Cote d’Ivoire, Egypt, 
Eritrea, Mauritania, and Senegal), the criminal code specifies an elevated penalty (prison and/or 
fine) specifically for health care providers who perform FGM/C, in addition to the possibility of 
suspending their licenses (Shell-Duncan, Wander, Hernlund, & Moreau, 2013). 
Despite this emerging consensus, medicalised cutting is still occurring. Rates of medicalisation are 
purportedly continuing to climb despite mounting criticism, scrutiny, and legal regulation (Kimani & 
Shell-Duncan, 2018; WHO, 2010). Medical ethicists have argued that the unacceptably slow 
progress toward abandonment justifies the endorsement of “de minimis” forms of FGM/C that do 
not carry long-term medical risks (Arora & Jacobs, 2016). And soon courts of law will be asked to 
adjudicate on two landmark medicalisation cases. An upcoming case in the U.S. will decide 
whether medical practitioners who performed genital scraping on girls have violated a federal ban 
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on FGM/C (Belluck, 2017). While in Kenya a doctor has filed a claim that the ban on FGM/C among 
adult women is unconstitutional by denying women a right to culture, to make choices about their 
body, and have access to medical care should they elect to undergo this procedure (Bhalla, 2018). 
Against this background, concerns remain as to whether medicalisation may be legitimising the 
practice and impeding progress toward abandonment (Doucet, Pallito, & Groleau, 2017; Kimani & 
Shell-Duncan, 2018). In an effort to fill this gap, we examine data on medicalisation from nationally- 
representative survey data from 26 countries to make evidence-based inferences regarding some 
key debates surrounding the effects of medicalisation. First, we explore the patterns and trends in 
medicalisation. Second, to investigate the claim that medicalised cutting may slow rates of 
abandonment of FGM/C, we examine association between medicalisation and rates of change in 
prevalence of FGM/C, and the association between rates of medicalisation and level of support for 
the continuation of FGM/C. 
Methods 
Data Sources  
Data on medicalisation of FGM/C are available from nationally-representative data from 26 
countries in Africa and the Middle East. Reliable nationally-representative data have been 
generated through several major household surveys: the DHS, the Multiple Indicator Cluster 
Surveys (MICS), the Egypt Health Issues Survey (HIS), and the Eritrea Population Health Survey 
(PHS). Each survey asks a sample of women of reproductive age (15-49 years) about their own 
FGM/C status, as well as the person who performed the cutting for those who have undergone 
FGM/C. Women with at least one living daughter are asked the same questions about at least one 
daughter, usually the most recently cut daughter or, in recent MICS and DHS surveys, all daughters 
between ages 0-14 years. The survey also asks women their opinion as to whether the practise of 
FGM/C should continue. Data were drawn from the final reports prepared for each survey. Where 
data were not available in final reports, they were obtained from the publicly available data sets.  
Variables 
Women’s self-reported data on FGM/C come from the surveys described above. For each survey 
a random sample of women aged between 15 and 49 years was drawn using a two-stage cluster 
sampling procedure. Data on daughters were reported by their mothers. Data on support for 
continuation of FGM/C was obtained from women who positively replied to a question about having 
ever heard of FGM/C. Most surveys posed the question as “Do you think this practice should 
continue? Or should it be discontinued?” This was followed by pre-coded responses: continued, 
discontinued, and it depends/not sure (UNFPA-UNICEF, 2013). The number of women who 
indicated they think FGM/C should continue was used to compute the percent of women who 
favour continuation of the practice. Questions about practitioners of FGM/C on women or on their 
daughters vary in form across surveys, and survey reports compiled categories in different forms. 
In many instances data on health personnel are divided as doctor and nurse/midwife/other health 
worker. Data on traditional circumcisers are often categorised as traditional practitioner and ‘other 
traditional practitioner’. Some surveys have unique categories; for instance, the Egypt survey asks 
about the three categories (daya, barber, and ghagarie) that are found only in the Egypt female 
genital cutting module. Data from The Gambia and Yemen are reported in only two categories: 
health personnel and traditional practitioners. To allow comparisons across countries, we grouped 
practitioners into the two larger categories: traditional practitioners and health personnel. In the 
Cameroon survey (DHS 2004), data on type of practitioner of FGM/C were collected for women, 




The data reported throughout this report are weighted based on sampling design. Descriptive 
statistics to facilitate comparisons across countries and to discern patterns and trends are 
presented as frequencies and percentages. The outcome variables of interest are national 
prevalence of FGM/C, rates of medicalisation (defined as the percent of girls and women with 
FGM/C who report cutting performed by a health professional), percent of women who support the 
continuation of FGM/C, and type of health personnel who performed cutting (doctor versus nurse 
midwife or other health professional). For countries with consecutive surveys with comparable data 
on medicalisation and prevalence of FGM/C (Benin, Burkina Faso, Chad, Cote d’Ivoire, Egypt, 
Eritrea, Kenya, Mali, Niger, Nigeria, Senegal, Sudan, Togo, and the United Republic of Tanzania), 
trends across time were plotted and described. The U.S. Census Bureau’s International Data Base 
(U.S. Census Bureau) was used to obtain midyear population estimates by five-year age cohorts 
by country for the year in which the survey data were collected. To estimate the total number of 
women aged between 15 and 49 years who are cut in any one of the countries, we tally the total 
number of women in this age range in the year that the most recent survey was conducted and 
multiply the number by the prevalence of FGM/C among women aged 15-49 years (based on self-
reported FGM/C status). The total number of women cut by health practitioners was estimated by 
multiplying the total number of women cut by the medicalisation rate. Following the methods of 
UNICEF (2013) we also use prevalence figures on age-specific cohorts to determine trends in 
change in FGM/C prevalence. Specifically, we compare the prevalence of FGM/C in the oldest age 
cohort (45-49 years) to the prevalence in the youngest age cohort (15-19 years). The percent 
change between the oldest and youngest age cohorts is used to compute the rate of decline in 
FGM/C. The Pearson correlation coefficient was computed between rates of medicalisation among 
daughters and two different measures: 1) percent of change in the prevalence of FGM/C between 
the eldest and youngest cohort, and 2) proportion of women aged 15-49 years who support the 
continuation of FGM/C.  
Expert group analysis 
To maximise understanding of the data, the interpretation of results was done in consultation with 
a panel of experts on medicalisation of FGM/C who are conducting focused studies on this topic 
in their own countries. The experts interviewed were Samuel Kimani from the Africa Coordinating 
Centre for the Abandonment of FGM/C (ACCAF), University of Nairobi, Kenya; Nafisa Bedri and 
Yussra Mohamed from Gender and Reproductive Health and Rights Resources and Advocacy 
Center (GRACe) and Ahfad University for Women, Khartoum, Sudan; Salma Abou Hussein from 
Population Council in Cairo, Egypt; and Otibho Obianwu and Adetayo Adetunji from Population 
Council, Abuja, Nigeria. They offered possible interpretations of the data presented in this study 
based on their own research on medicalisation and offered an expert consensus on the 
conclusions reached at the end of this paper. This took place during a meeting of partners involved 
in the Evidence to End FGM/C: Research to Help Girls and Women Thrive research consortium, 
held in Nairobi, Kenya in February and March 2018. 
Results  
Patterns and trends in medicalisation 
Self-reported data on the prevalence of FGM/C and person who performed cutting are reported in 
Table 1. The prevalence of FGM/C among women aged 15-49 ranges from as low as 1-2 percent 
(Cameroon and Niger) up to 97 percent (Guinea). Among women with FGM/C, rates of 
medicalisation among women aged 15-49 are highest in five countries: Sudan (67%), Egypt (42%), 
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Guinea (15%), Kenya (15%), and Nigeria (13%). Elsewhere, medicalised cutting is rare and 
restricted to geographically defined pockets. 
Table 1. Prevalence of FGM/C, medicalisation and total number of women (age 15-49) cut by health 


















Total Cut by 
Health 
Professionals 
Benin MICS 2014 9.2 0.9 2,367,594 217,819 1,960 
Burkina Faso MICS/DHS 
2010 
75.8 0.2 3,688,866 2,796,160 5,592 
Cameroon DHS 2004 1.4 4.0 4,098,869 57,384 2,295 
CAR MICS 2010 24.2 2.3 1,172,050 283,636 6,524 
Chad DHS 2014-
15 
38.4 0.9 2,785,163 1,107,229 9,626 
Côte d’Ivoire MICS 2016 36.7 1.0 6,117,646 2,022,276 22,452 
Djibouti MICS 2006 93.1 6.0 193,365 180,023 10,801 
Egypt HIS 2015 87.2 42.2 23,857,123 21,534,578 8,820,646 
Eritrea PHS 2010 83.0 0.3 1,289,441 869,559 3,211 
Ethiopia DHS 2016 65.2 1.0 24,091,527 15,707,676 157,077 
Gambia DHS 2013 74.9 0.3 486,629 364,485 1,093 
Ghana MICS 2011 3.8 1.2 6,041,140 229,563 2,755 
Guinea DHS 2012 96.9 15.4 2,518,996 2,440,907 375,900 
Guinea-Bissau MICS 2014 44.9 0.6 419,549 189,846 1,130 
Iraq MICS 2011 8.1 6.3 7,623,574 617,509 38,903 
Kenya DHS 2014 21.0 14.7 10,877,750 2,284,328 335,796 
Mali MICS 2015 82.7 2.3 3,807,075 3,221,836 72,414 
Mauritania MICS 2015 66.3 11.9 934,407 580,939 3,112 
Niger DHS 2012 2.0 0.0 3,423,589 68,472 0 
Nigeria MICS 
2016-17 
18.4 12.7 42,889,199 9,787,758 939,102 
Senegal DHS 2016 22.7 0.5 3,625,663 854,176 0 
Sierra Leone DHS 2013 89.6 1.8 1,391,263 1,246,572 13712 
Sudan MICS 2014 86.6 66.8 8,752,649 7,579,794 5,063,302 
Togo DHS 2013-
14 
4.7 0.5 1,755,425 63,105 413 
Tanzania DHS 2015-
16 
10.0 1.8 11,902,487 1,482,789 21,424 
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Table 1. Prevalence of FGM/C, medicalisation and total number of women (age 15-49) cut by health 


















Total Cut by 
Health 
Professionals 






* To calculate the total number of women cut by health professionals, data on mid-year population size of women aged 
15-49 years (in the year the survey was conducted) were obtained from the U.S. Census Bureau International 
Database. 
CAR: Central African Republic 
 
In the 26 countries for which we have data on medicalisation, most women with FGM/C (79%) 
report being cut by a traditional practitioner; and 21 percent, totalling 15,941,674, were reportedly 
cut by a health care provider. Of women who report medicalised cutting, more than half (55%) 
reside in Egypt alone. Ninety-three percent of women who were cut by a health professional live 
in just three countries: Egypt, Sudan, and Nigeria (Figure 1). 
 
Figure 1. Geographic distribution of women aged 15-49 years with FGM/C who report having 




In 16 out of 24 countries, less than 10 percent of daughters with FGM/C were cut by medical 
professionals (Figure 2). Overall, like in all women, the majority of FGM/C is most often performed 






Egypt Sudan Nigeria Guinea Kenya All other countries
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Figure 2. Type of practitioner of FGM/C on daughters 
 
 
In eight countries, rates of medicalised cutting among daughters are 10 percent or higher (Figure 
3). Comparing rates of medicalisation among mothers and daughters, rates are higher among 
daughters in each of these countries except Nigeria. The trend toward increased medicalisation in 
daughters, as compared to mothers, is most pronounced in Egypt, where medicalisation rates 
among daughters (78%) are nearly twice those among women (42%). 
 
Figure 3. Comparison of rates of medicalisation among mothers and daughters 
 









































From the results, two categories of health professionals were identified to perform FGM/C on 
daughters: 1) doctors, and 2) nurses, midwives, or other health professionals for the same 
countries (i.e., Sudan, Egypt, Guinea, Kenya, Nigeria, Djibouti, and Iraq) except Yemen, where 
only aggregated figures are reported (Figure 4). Egypt is unique in that doctors most commonly 
undertake FGM/C. In most countries where health care providers provide FGM/C on daughters, it 
is carried out by nurses, trained midwives, or other trained healthcare professionals.  
 
Figure 4. Type of practitioner who performed FGM/C on daughters 
 
 
Association between medicalisation and change in prevalence of FGM/C 
A key question is whether medicalisation counteracts efforts to eliminate FGM/C and reduces rates 
of decline in FGM/C. This is a causal question for which counterfactual data do not exist; that is, 
we cannot answer the question, “would rates of decline have been higher had medicalisation not 
occurred?” With the data at hand, the change in prevalence of FGM/C is examined two ways:  first 
by computing the percent change in prevalence between the youngest (15-19 years old) and oldest 
(40-49 year old) age cohorts of women, and second, by examining change in prevalence of FGM/C 
in women 15-49 years across successive surveys.  
Comparison of prevalence in these age cohorts are shown in Figure 5. The data show that the 
















Doctor Nurse/Midwife/Other Health Professional
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Figure 5. Comparison of prevalence of FGM/C in the oldest (45-49) and youngest (15-19) age 
cohorts* 
 
*For Ethiopia the oldest age cohort is 35-49 years because of small n.  
 
The rate of change across cohorts is computed as the percent change in prevelance between the 
oldest and youngest age cohorts. Figure 6 shows the association between the percent change in 
FGM/C prevalence in the oldest and youngest age cohorts and rates of medicalisation among 
daughters. The data show that the countries with the highest rates of medicalisation among 
daughters (Egypt, Sudan, Guinea, and Djibouti), have a low percent change in prevalence of 
FGM/C. At the same time, the country with the greatest decline in FGM/C across age cohorts, 
Kenya, has a 20 percent rate of medicalisation among daughters. Low rates of medicalisation are 
found in countries with widely ranging rates of change in FGM/C. Overall, there is not a significant 
correlation between the rate of decline in FGM/C and medicalisation (r=-0.25, not significant).  
Thus, it is not clear that motivation to seek medicalised cutting is influences by rates of 
abandonment of FGM/C. 
 



























Prevalence FGM/C 45-49 Prevalence FGM/C 15-19
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Figure 6. Relationship between medicalisation rates among daughters and percent change in 
prevalence of FGM/C between youngest (15-19 years) and oldest (45-49 years) cohorts of 
women* 
 
*Country codes: BEN – Benin; BFO – Burkina Faso; CAR – Central African Republlic; CHA – Chad; CDI - Côte 
d’Ivoire; DJI – Djibouti; EGY – Egypt; ERI – Eritrea; ETH – Ethiopia; GAM – Gambia; GHA – Ghana; GUI – Guinea; 
GBI – Guinea Bissau; IRA – Iraq; KEN – Kenya; MAL – Mali; MAU – Mauritania; NGR – Niger; NGA- Nigeria; SEN 
– Senegal; SLE – Sierra Leone; SUD – Sudan; TOG – Togo; TAN – United Republic of Tanzania; YEM – Yemen 
 
Members of the expert panel on medicalisation suggested that national-level figures may mask 
regional variation in changes in FGM/C prevalence and medicalisation with countries, and that 
local contexts and drivers of medicalisation vary substantially. For instance, in Nigeria, where Type 
I FGM/C is common, medicalisation is not being driven by parents’ concerns about safety of the 
practice (it is already seen as a relatively benign practice) (Obianwu, personal communication). 
Instead, as women seek medicalised delivery services, FGM/C is being offered as part of routine 
neonatal services (Obianwu, Adetunji, Dirisu, Ishaku, & Adebajo, 2017). By contrast, in Egypt and 
Sudan, medicalisation has been linked to policies aimed at regulating harm (Bedri and Mohamed, 
personal communication, Hussein, personal communication), and may entrench the practise of 
FGM/C (Bedri, Sherfi, Elhadi, Rodwan, & Elamin, In preparation; El-Gibaly & Aziz, In preparation). 
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Trends in prevalence of FGM/C among women aged 15-49 years and medicalisation rates among 
daughters were examined through repeat survey data (available for 13 countries). Discernible 
changes in medicalisation are detectable in only three countries: Egypt, Kenya, and Sudan. In 
Sudan, consecutive surveys from 2010 and 2014 also revealed a sharp increase in daughters’ 
medicalised cutting, rising from 55 percent to 78 percent. Over this period, the prevalence of 
FGM/C among women aged 15-49 years remained steady (88% to 87%). In Egypt between 1995 
and 2015, rates of medicalised cutting among daughters rose sharply from 55 percent to 74 
percent. During this period, the prevalence of FGM/C among women aged 15-49 years declined 
from 97 percent to 87 percent. Data from Kenya shows a mixed pattern of medicalisation and 
prevalence rates of FGM/C across successive surveys. There was an increasing trend to have 
FGM/C performed by health care personnel (Figure 7), rising from 34 percent in 1998 to 41 percent 
in 2008-09, followed by a subsequent drop in 2014. This fluctuation in medicalisation rates has 
occurred simultaneously with a substantial decrease in the prevalence of FGM/C among women 
aged 15-49 years, dropping appreciably from 38 percent in 1998 to 21 percent in 2014. However, 
these data do not allow us to test causal associations nor whether the decline in FGM/C might 
have been even larger if health professionals were not performing FGM/C. Nonetheless, the results 
for Kenya indicate that medicalisation rose whilst FGM/C prevalence fell. The expert panel member 
from Kenya (Samuel Kimani) suggested that this pattern may be attributable to the fact that in 
Kenya, decreases in the prevalence vary dramatically along lines of ethnicity, and medicalisation 
is concentrated in communities that have been resistant to abandoning FGM/C (Kimani & Kabiru, 
In preparation; Shell-Duncan, Gathara, & Moore, 2017). 
 
Figure 7. Trends in prevalence of FGM/C and medicalisation in Kenya 
 
 
Association between medicalisation and support for the continuation of FGM/C 
A related question is whether medicalisation influences support for the continuation of FGM/C. It 
has been posited that the availability of medicalised cutting may lead to continued support for 
FGM/C by creating the impression that it can be performed safely. Alternatively, mothers who opt 
for medicalised cutting for their daughters may be persuaded about the harmfulness of FGM/C and 
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Women’s self-reported support for the continuation of FGM/C ranges from as high as 72 percent 
in Mali to as low as 1.5 percent in Ghana. Figure 8 plots the percentage of women who support 
the continuation of FGM/C against rates of medicalisation among daughters. The results show that 
there is not a significant correlation between medicalisation and higher support for continuation of 
FGM/C (r=0.50, not significant). This finding may also be linked to the fact that there is tremendous 
variation in factors motivating medicalisation and is not universally linked to concerns about health 
risks (expert panel and Kimani & Kabiru, in preparation; Obianwu et al., 2017). 
 
Figure 8. Relationship between medicalisation rates among daughters and the proportion of 
mothers who support the continuation of FGM/C* 
 
*Country codes: BEN – Benin; BFO – Burkina Faso; CAR – Central African Republlic; CHA – Chad; CDI - Côte d’Ivoire; DJI – 
Djibouti; EGY – Egypt; ERI – Eritrea; ETH – Ethiopia; GAM – Gambia; GHA – Ghana; GUI – Guinea; GBI – Guinea Bissau; IRA 
– Iraq; KEN – Kenya; MAL – Mali; MAU – Mauritania; NGR – Niger; NGA- Nigeria; SEN – Senegal; SLE – Sierra Leone; SUD – 







This study draws on population-based survey results from 26 countries and the perspectives of 
members of the expert panel conducting focused studies on the medicalisation of FGM/C. Findings 
from the study reveals an estimated 21 percent of women with FGM/C had the procedure 
performed by a health care provider (doctor, nurse, trained midwife, or other health professional), 
while the majority (79%) reported being cut by a traditional circumciser. All told, nearly 16 million 
girls and women experienced medicalised cutting. Medicalised cutting is highly concentrated 
geographically. Of women who report having been cut by a health care provider, more than half 
(55%) live in Egypt alone. Overall, 93 percent of women who reportedly experienced medicalised 
cutting live in Egypt, Sudan, and Nigeria. Elsewhere, medicalisation is rare or restricted to 
geographic pockets. Comparing medicalisation rates between survey respondents and their 
daughters, rates of medicalisation are increasing sharply in both Egypt and Sudan, but not in 
Nigeria. 
Egypt appears to be unique in terms of being the only country in which medicalised cutting is 
carried out primarily by doctors, as opposed to nurses or other health workers. This trend is 
historically linked to health policies from the 1990’s. In an effort to reduce the harm of what was 
viewed as an inevitable practice, the Ministry of Health issued a decree that lifted a 35-year ban 
on performing FGM/C in public hospitals in 1994 (El-Gibaly, Ibrahim, Mensch, & Clark, 2002). The 
Ministry asked state hospitals to set aside one day a week for performing FGM/C “by trained 
physicians under hygienic conditions” (Reefat, 2009). This policy came under sharp criticism, was 
reversed to banning FGM/C in both state and private hospitals. A “loophole”, however, allowed for 
“medically necessary circumcision,” (Modrek & Liu, 2013) and was not closed until 2007 by a 
Ministerial Decree prohibiting doctors, nursing staff, or others from performing FGM/C, whether in 
governmental or non-governmental hospitals. This decree was bolstered by the adoption of a 2008 
law making FGM/C a crime punishable by imprisonment or fine. In January 2015, the first 
successful FGM-related prosecution took place, convicting a doctor of involuntary manslaughter 
for his role in the death of a 13-year-old girl and sentencing him to two years and three months in 
prison (Michaelson, 2016). In 2016, the law banning medical professionals from performing FGM/C 
in either state or privately-run clinics was amended to raise the maximum sentence from three to 
15 years in prison (Sirgany, 2016). 
In Sudan, where 67 percent of women with FGM/C report having undergone medicalised cutting, 
the procedure is in most instances performed by trained midwives. During the colonial era, 
government officials introduced measures intended to reduce the harm of infibulation by restricting 
the severity of cutting. Knowing that traditional birth attendants were the primary providers of 
FGM/C, midwifery schools established in Sudan in the 1920’s taught a modified or “intermediate” 
(mitwasit) form of cutting that involved the same amount of cutting, but less stitching (Boddy, 2016). 
In 1946, a law was passed banning infibulation but allowing less severe forms of cutting. The law 
was ratified in 1956 when Sudan became independent but was dropped from the 1983 Penal Code. 
Although the Sudanese Medical Council has now banned FGM/C by any medical professional 
(Sharfi, Elmegboul, & Abdella, 2013), there is no national law regulating FGM/C or medicalisation. 
Currently, WHO is conducting trials of interventions aimed at de-medicalisation of FGM/C in two 
states (Ahmed, 2017; Bukuluki, 2017). Such investigations are needed, as it is unclear how de-
medicalisation might influence strategies aimed at abandonment of FGM/C. One recent study in 
Egypt found that when a daughter’s peers had undergone medicalised FGM/C, her own likelihood 
of being cut was in some instances reduced. The author suggests medicalisation may reflect 
shifting social norms that open change possibilities, including abandonment of FGM/C (Naguib, 
2012). Whether this is also true in Kenya is unclear (Kimani & Kabiru, In preparation). 
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In Nigeria, girls and women who have experienced medicalised cutting are in most cases 
reportedly cut by nurses (Ashimi, Aliyu, Shittu, & Amole, 2014; Obianwu et al., 2017). A recent 
qualitative study in Nigeria questions how often these providers are formally trained nurses or 
informally trained auxiliary nurses or midwives (Obianwu et al., 2017). It also showed that 
medicalisation is not driven primarily by harm reduction concerns, as it is widely considered to be 
a relatively benign procedure; instead it appears to be linked to an uptake in labour and deliver 
services in centres that offer FGM/C as part of routine neonatal care options (Obianwu et al., 2017). 
Findings from the study also indicate that there is no significant correlation between rates of 
medicalisation among daughters and rates of decline in prevalence of FGM/C at the national level. 
Further multivariate analyses are needed to control for potentially confounding factors and account 
for subnational variation. Repeat survey data on medicalisation among daughters are available for 
13 countries, and substantial changes in medicalisation are found in Egypt, Kenya, and Sudan. In 
Egypt and Kenya, medicalisation has occurred alongside declines in rates of FGM/C. At the same 
time, Sudan shows persistently high rates of FGM/C alongside rising medicalisation rates. Whether 
medicalisation is hindering this decline is unclear but can be addressed in focused research. 
Debates have also centred on whether medicalisation legitimises the practise of FGM/C by 
creating an impression that the procedure may be performed safely, or whether parents who opt 
for medicalised cutting may be more open to change in FGM/C and less likely to support 
continuation of the practice (Dawson et al., 2015; Modrek & Sieverding, 2016; Naguib, 2012). To 
investigate these claims, we examined the association between rates of medicalisation among 
daughters and mothers’ stated support for the continuation of FGM/C and found no significant 
correlation. 
There are a number of limitations in this study. We examined trends and correlations, which may 
be influenced by outliers, and as such further multivariate analyses are needed to control for 
potentially confounding factors, and to examine within-country patterns. Moreover, there are some 
concerns regarding the validity of the survey data used in this study. Self-reported data on FGM/C 
need to be treated with caution as inaccuracies may arise because of unwillingness to disclose 
having undergone FGM/C due to the sensitivity of the topic or because of criminalisation of the 
practice (Askew, 2005; Shell-Duncan, 2017). Additionally, particularly when FGM/C is performed 
at an early age, women may be unaware of whether they have been cut or the extent of the cutting 
or may not accurately recall the circumstances surrounding the procedure. A number of studies 
have attempted to determine the reliability of self-reports of FGM/C status (being cut or not) by 
verifying them through clinical examinations, and have reported variable rates of concordance 
(Adinma, 1997; Elmusharaf, Elhadi, & Almroth, 2006; Klouman, Manongi, & Klepp, 2005; Morison, 
Dirir, Elmi, Warsame, & Dirir, 2004; Msuya et al., 2002; Snow, Slanger, Okonofu, Oronsaye, & 
Wacker, 2002). The general consensus is that self-reports of being cut or not provide reasonably 
reliable estimates of FGM/C prevalence (Yoder & Wang, 2013).  
Conclusion 
Among girls and women aged 15-49 who have undergone FGM/C, 21 percent have been cut by 
professional health care workers. For those working to deter or prevent medicalised cutting, it is 
important to recognise that it is concentrated in three countries namely Egypt, Sudan, and Nigeria. 
Mother-daughter comparisons indicate that medicalisation rates are increasing in several 
countries, most sharply in Egypt where rates have more than doubled. Further studies are needed 
to understand the rationale for selecting medicalised cutting, and whether or how medicalisation 
influences readiness to change FGM/C. The data do not show a significant association between 
medicalised FGM/C among daughters and rates of decline in prevalence of or support for the 
continuation of the practice. An expert panel on medicalisation suggested that it is likely that 
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national-level figures mask important subnational variation in changes in FGM/C prevalence and 
medicalisation rates, as well as differences in factors driving medicalisation. Rising rates of 
medicalisation occur alongside both modest declines in FGM/C (in Egypt) and substantial declines 
in FGM/C (Kenya). In Sudan, medicalisation rates rose while the prevalence of FGM/C remained 
steady. Whether medicalisation is hindering abandonment of FGM/C is unclear. The question 
remains as to whether this shift represents reluctance to stop an intractable practice or signifies 
openness to change that can be leveraged to promote abandonment. This is a pressing matter 
that influences actions needed to achieve the international community’s recently adopted set of 
SDGs, including target 5.3.2 calling for the elimination of all harmful traditional practices such as 
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